Could a cancer drug combo slow Alzheimer's?
NCT ID NCT04785300
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This early-stage study tests whether two drugs, dasatinib and quercetin, are safe and practical for people with mild cognitive impairment or Alzheimer's disease. The drugs aim to clear aging cells that may contribute to brain decline. Twenty participants aged 55 and older will be monitored for side effects and tolerability over the study period.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple questionnaire empower dementia caregivers after hospital stays?
- Could your heart hold the key to Alzheimer's prevention?
- Could your brain help unlock Alzheimer's secrets?
- Can a nudge in your chart unlock Life-Saving genetic clues?
- Can a simple test predict Alzheimer's before symptoms worsen?
- Can a Voice-Based app map healthy brain aging across 80 years?